Stilbene Treatment Reduces Stemness Features in Human Lung Adenocarcinoma Model

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Lung cancer is a challenging tumor due to aggressive proliferation, metastasis, and cancer stem cells (CSCs).
• Natural compounds like resveratrol (RSV) are explored for cancer chemoprevention.
• 4,4'-dihydroxy-trans-stilbene (DHS), an RSV analogue, shows enhanced activity in preclinical models.

Purpose of the Study:

• To investigate the effects of DHS and RSV on A549 lung cancer cells.
• To analyze the impact of these stilbenes on cancer stem cell (CSC) features, focusing on the side population (SP) fraction.

Main Methods:

• Treatment of A549 lung cancer cells with DHS and RSV.
• Isolation of CSCs via side population (SP) sorting.
• Analysis of cell cycle progression, clonogenicity, soft agar colony formation, stemness marker expression, and spheroid formation.

Main Results:

• Both DHS and RSV inhibited cell cycle progression; DHS reduced the S phase, while RSV increased it.
• DHS treatment led to a 50% reduction in clonogenicity and soft agar colony formation.
• DHS and RSV decreased stemness marker expression in A549 cells and SP fraction.
• DHS significantly reduced spheroid formation and SOX2 levels in SP cells more than RSV.

Conclusions:

• Stilbenes, particularly DHS, impact stemness features in A549 lung cancer cells and their SP fraction.
• DHS demonstrates potent anticancer effects, including inhibition of proliferation and stemness.
• DHS shows potential as an anticancer agent, usable alone or in combination therapy for lung cancer.